[特殊患者群体的特殊禁食要求]
Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS
|November 25, 2025
概括
术前禁食指南正在发展,超越了志向风险,考虑了患者的福祉. 新的建议侧重于个性化,更短的禁食期,特别是在儿童和老年人等高风险群体.
科学领域:
- 麻醉学 麻醉学
- 在外科手术期间的医学.
- 胃肠病学 胃肠病学
背景情况:
- 术前禁食指南传统上专注于降低吸收风险.
- 最近的研究强调了长时间禁食的病理生理影响.
- 目标是转向更短,以患者为中心的禁食协议.
研究的目的:
- 更新关于手术前禁食的建议.
- 为了确定患有由于胃空气延迟而增加吸入风险的患者群体.
- 为弱势群体提供最佳实践指导.
主要方法:
- 关于手术前禁食的当前文献和指导方针的审查.
- 识别延迟胃空化的危险因素.
- 对儿童,老年人和孕妇的具体考虑的分析.
主要成果:
- 延迟胃排空是术后风险的一个重要因素.
- 并发症 (例如糖尿病,帕金森病) 和药物 (例如阿片类药物,GLP-1激动剂) 可以延迟胃排空.
- 儿童,老年人,虚弱个体和孕妇特别容易受到长期禁食的影响.
结论:
- 术前禁食建议应该是个性化的,考虑到吸收风险和长时间禁食的负面影响.
- 脆弱的患者群体需要特别注意,以防止过长的禁食时间.
- 这份概述是针对特定的术前禁食挑战的最佳实践建议.
相关概念视频
Metabolic States of the Body: Fasting and Starvation
2.7K
During the initial hours of fasting, the body uses up its glycogen stores as an energy source. Once these glycogen reserves are depleted, the body begins breaking down stored triglycerides and structural proteins. During this stage, glycerol becomes a key substrate for gluconeogenesis, while free fatty acids undergo beta-oxidation to provide energy for tissues, such as skeletal muscle. In the fasting state, the body spares protein breakdown as much as possible to conserve muscle and structural...
2.7K
Bioavailability Study Design: Healthy Subjects Versus Patients
136
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
136
Metabolic States of the Body: The Postabsorptive State
1.2K
The postabsorptive state usually starts about four hours after a meal and lasts until the next meal is eaten. During this time, the digestive system stops absorbing nutrients, and the body uses stored energy reserves to maintain stable blood glucose levels.
Initially, glycogen stored in the liver is broken down to release glucose into the bloodstream, while glycogen in the muscles is broken down to supply glucose for energy directly within the muscle cells. As glycogen stores diminish,...
Initially, glycogen stored in the liver is broken down to release glucose into the bloodstream, while glycogen in the muscles is broken down to supply glucose for energy directly within the muscle cells. As glycogen stores diminish,...
1.2K
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding
789
Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
789
Hypoglycemia and Glucagon
779
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
779
Heart Failure VI: Adjunct Therapies
239
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
239


